Harlan provides non-clinical contract research, research models, animal diets, and services to the pharma/biopharma industry, medical device, crop protection and chemical industries, as well as universities, government, and other research organizations.
Brian Cass, chief executive officer of Huntingdon Life Sciences, said, "We are excited by the acquisition of Harlan, a highly respected leader in their market sectors. This acquisition is precisely in line with our strategy to broaden our support for the pharmaceutical, crop protection and chemical industries, as well as universities, government, and other research organizations. Our two companies have a long heritage and together we will maintain and build on our reputation for high quality science and innovation."
Harlan chief executive officer Hans Thunem said, "Merging these two leading companies, with their complementary product and service offerings, positions the combined organization as a global leader in supporting the growing market for outsourced research and development. Brian and his newly expanded team bring enormous depth and experience to the increasingly complex challenges facing non-clinical and pre-clinical researchers."